2026年1月14日(交易时段后)，公司与高盛(亚洲)有限责任公司及香港上海汇丰银行有限公司签署了配售 协议。根据配售协议，公司同意委任配售代理而配售代理各自同意(而非共同，亦非共同及个别)出任公 司代理，并尽力促使若干承配人按照配售协议所载条款及条件，按每股配售股份22.82港元认购公司根 据一般发行授权拟发行的5844.0762万股新H股。 康龙化成（300759）(300759.SZ)公告，公司拟根据2024年年度股东大会审议通过的《关于股东大会给 予董事会增发公司H股股份一般性授权的议案》项下股东大会对董事会增发H股股份的授权，新增发行 境外上市外资股(H股)。 ...

药明康德 ：将以每股1元人民币的价格配售5840万股新H股。 ...

本文作者可以追加内容哦 ! 配售股份数目分别占截至本公告日期现有已发行H股总数及现有已发行股份总数约19.86%和3.30%。配 售价每股配售股份港币22.82元，较1月14日(即配售协议签署的最后交易日)香港联交所所报收市价每股 H股港币24.94元折价约8.50%。配售股份将根据一般发行授权发行。 配售所得款项净额预期约为13.19亿港元，并将按以下方式动用：约70%将用于公司的项目建设，以加 强本公司实验室服务设施、药物工艺开发及生产设施的能力及产能；约10%将用于偿还银行贷款及其他 借款，以优化公司的资本结构；及约20%将用于补充营运资金及作其他一般公司用途。上述募集资金用 途届时会根据最终的发行规模进行相应调整。追加内容 格隆汇1月15日丨康龙化成(03759.HK)发布公告，2026年1月14日，公司与配售代理(即高盛与汇丰)订立 配售协议，据此，各配售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并尽力促使承配人 按配售协议所载的条款及条件，以每股配售股份的配售价格认购总计5844.08万股新H股。 ...

假设所有配售股份获全数认购，配售所得款项总额预期约为13.34亿港元。配售所得款项净额预期约为 13.19亿港元(每股配售股份的净价将约为22.56港元)，并将按以下方式动用：约70%将用于公司的项目建 设，以加强公司实验室服务设施、药物工艺开发及生产设施的能力及产能;约10%将用于偿还银行贷款 及其他借款，以优化公司的资本结构;及约20%将用于补充营运资金及作其他一般公司用途。 智通财经APP讯，康龙化成(03759)发布公告，于2026年1月14日，公司与配售代理订立配售协议，各配 售代理各自同意(而非共同，亦非共同及个别)出任公司代理，并尽力促使承配人按配售协议所载的条款 及条件，以每股配售股份的配售价格认购总计5844.08万股新H股。配售股份数目占紧接完成后经发行配 售股份扩大后的已发行H股总数及已发行股份总数分别约16.57%和3.19%。配售价每股配售股份港币 22.82元较2026年1月14日香港联交所所报收市价每股H股港币24.94元折价约8.50%。 ...

公益性是医疗卫生事业的基本属性，也是深化医药卫生体制改革的根本导向。《中共中央关于制定国民 经济和社会发展第十五个五年规划的建议》提出"以公益性为导向深化公立医院编制、服务价格、薪酬 制度、综合监管改革"，牵住了公立医院改革的"牛鼻子"。这4项改革是一个有机整体，共同支撑公立医 院的公益属性。 编制改革重点是通过增强人员稳定性和归属感为实现公益性创造条件。推进建立公立医院编制动态调整 机制，积极破除人才流动的体制障碍，实现医联体内的人员流动和编制调剂使用，使人才这一核心资源 能够根据公众健康需要高效配置，让优秀医务人员能够下沉基层、流动服务，更好支撑公益性的实现。 政府投入是公益性的支撑保障。探索建立与经济社会发展水平相适应、与财政收入增长相协调的财政投 入增长机制。 接下来，应进一步筑牢投入保障的根基，建立与公益性定位相适应的稳定财政补偿与长效投入机制，确 保机构"不为生存所困"。筑牢服务供给的根基，通过深化医防融合与做实家庭医生签约，强化其居民健 康"守门人"的核心职能，确保服务不偏离方向。筑牢绩效评价的根基，建立以健康结果和服务质量为核 心的公益性评价体系，确保运行不偏离轨道。 （作者系国家卫生健康委医 ...

Group 1 - The article does not contain any relevant content regarding company or industry insights [1]

（来源：南京晨报） 转自：南京晨报 脑卒中后遗症不仅给患者带来身体上的痛苦，更让整个家庭背负沉重负担。近日，江苏省人民医院（南 京医科大学第一附属医院、江苏省妇幼保健院）中医科发挥精准的中医辨证和个性化方药治疗优势，帮 助一位饱受14年脑出血后遗症困扰的患者重获新生。 2025年9月9日中午，早已过了正常挂号时间，在江苏省人民医院中医科诊室外，一位中年女子被丈夫背 着，女儿在一旁恳求医生加号。该院丁炜主任医师看到这一幕，见患者行动艰难、家属神情焦急，当即 答应加号，并为患者进行了细致诊疗。 基于上述辨证结果，为李女士开具了个性化中药方剂，以益气活血药物筑牢气血根基，辅以祛风化痰通 络药物疏通经络瘀阻。令人欣喜的是，服用14剂中药后，李女士右侧肢体疼痛、活动不利及发凉等症状 均显著改善，复诊时已能自行走入诊室；后续经过多次复诊调方，其症状持续好转——夜尿频繁、睡眠 不佳等问题逐步缓解，最终实现了生活基本自理。第三次复诊时，李女士的女儿激动地握着丁炜的手 说："是你们的精心治疗救了我妈妈，也救了我们一家！" 从卧床无法行动到可以行走、重获新生，李女士的巨大转变，离不开中医辨证施治理念的精准应用。据 了解，在后续多 ...

Group 1 - The core viewpoint of the news is the establishment of Kunming Xingqi Run Tong Medical Service Co., Ltd., which is fully owned by Kunming Xingqi Eye Hospital Co., Ltd. with a registered capital of 3 million RMB [1][2] - The legal representative of the newly established company is Huai Yihua [1] - The business scope includes medical services, sales of medical devices, health consulting services, and technology services among others [2] Group 2 - The company is registered in the health and social work industry, specifically under the hospital category [2] - The registered address of the company is located at Longxiang Street, Wuhua District, Kunming City, Yunnan Province [2] - The company is classified as a limited liability company with a business duration until January 14, 2026, with no fixed term thereafter [2]

Core Viewpoint - International Medical (000516) has experienced a significant stock price increase, closing at 6.19 yuan on January 14, 2026, marking a 9.95% rise and achieving consecutive trading limits for two days [1]. Trading Information Summary - On January 14, 2026, the net outflow of main funds was 171 million yuan, while retail investors saw a net inflow of 143 million yuan [3][7]. - International Medical was listed on the "Dragon and Tiger List" due to a cumulative price deviation of over 20% in the last three trading days, marking its first appearance on the list in the past five trading days [4][7]. Company Announcement Summary - The controlling shareholder, Shaanxi Century Xinyuan Commercial Management Co., Ltd., pledged 75 million shares to Chang'an International Trust Co., Ltd. on January 13, 2026. This pledge accounts for 12.17% of its holdings and 3.35% of the company's total share capital. After this pledge, the total pledged shares by Century Xinyuan reached 82.07% of its holdings, with a combined pledge by Century Xinyuan and its concerted actions amounting to 24.61% of the company's total share capital. The company stated that the pledge risk is controllable and will not lead to a change in actual control [5]. - The company confirmed that from January 12 to January 14, 2026, its stock price experienced a cumulative deviation exceeding 20%, constituting abnormal trading fluctuations. The company has verified that there are no undisclosed significant matters, and its operational situation remains normal. The controlling shareholder and actual controller did not trade the company's stock during this period. The company is not involved in the research, production, or sales of brain-computer interface products, and related application revenue has a minimal impact on its performance [6][7].

Core Viewpoint - Lianchi Hospital Group has submitted its prospectus to the Hong Kong Stock Exchange, marking its fifth attempt to go public after multiple unsuccessful attempts in various markets since 2015. The company aims to leverage its growth in the maternal and pediatric healthcare sector, despite facing increased short-term debt pressure due to recent acquisitions [1][6]. Financial Performance - Lianchi Hospital's revenue has shown steady growth, with 2024 revenue projected to reach 418 million yuan, a 17.39% increase from 2023's 356 million yuan. For the first nine months of 2025, revenue is expected to further increase by 20.3% to 359 million yuan [3][4]. - The net profit for 2024 is anticipated to grow by 19.14% to 67.59 million yuan, with a further increase of 17.67% to 55.51 million yuan for the first nine months of 2025 [3][4]. Business Focus - The company primarily focuses on the "one elderly, one child" sector, with maternal and pediatric medical services contributing approximately 90% of its revenue. In 2023, maternal and pediatric services accounted for 59.5% of total revenue, while orthopedic services contributed 28.3% [2][3]. Recent Acquisitions - To strengthen its market position, Lianchi Hospital has accelerated its expansion through acquisitions, including the purchase of Hefei Xinhai Maternity Hospital and Chongqing Changcheng Orthopedic Hospital in 2024 and 2025, respectively. However, these acquisitions have led to a significant increase in current liabilities, which rose to 195 million yuan by September 2025 [4][6]. Listing Journey - Lianchi Hospital's journey to go public has been tumultuous, with multiple changes in listing plans across different exchanges, including attempts at the New Third Board, ChiNext, Shenzhen Stock Exchange, and Beijing Stock Exchange. The decision to pursue a listing on the Hong Kong Stock Exchange is seen as a strategic move to meet capital needs and regulatory requirements [6][7]. Market Context - The choice to list in Hong Kong comes amid a trend of private hospitals like Zhuozheng Medical and Mingji Hospital also seeking listings there. The market response to these listings has been mixed, raising questions about the viability of Lianchi Hospital's decision [7].